Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study

References

• Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Reiner RC, Fullman N, Thompson RL, Abajobir A, Ahmed M, et al. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(9):909–10. doi:10.1016/S1473-3099(17)30276-1.
   PubMed Web of Science ®Google Scholar
• GBD Results Tool. Institute for health metrics and evaluation; [accessed 2021 Apr 7]. http://ghdx.healthdata.org/gbd-results-tool.
   Google Scholar
• ViewHub. International Vaccine Access Center (IVAC); [accessed 2021 Mar 25]. https://view-hub.org/ .
   Google Scholar
• Haider S, Chaikledkaew U, Thavorncharoensap M, Youngkong S, Islam MA, Thakkinstian A. Systematic review and meta-analysis of cost-effectiveness of rotavirus vaccine in low-income and lower-middle-income countries. Open Forum Infect Dis. 2019;6(4):ofz117. doi:10.1093/ofid/ofz117.
   PubMed Web of Science ®Google Scholar
• Kotirum S, Vutipongsatorn N, Kongpakwattana K, Hutubessy R, Chaiyakunapruk N. Global economic evaluations of rotavirus vaccines: A systematic review. Vaccine. 2017;35(26):3364–86. doi:10.1016/j.vaccine.2017.04.051.
   PubMed Web of Science ®Google Scholar
• Debellut F, Clark A, Pecenka C, Tate J, Baral R, Sanderson C, Parashar U, Kallen L, Atherly D. Re-Evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. Lancet Global Health. 2019;7(12):e1664–e1674. doi:10.1016/S2214-109X(19)30439-5.
   PubMed Web of Science ®Google Scholar
• Burnett E, Parashar UD, Tate JE. Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006–2019. J Infect Dis. 2020;222(10):1731–39. doi:10.1093/infdis/jiaa081.
   PubMed Web of Science ®Google Scholar
• Aliabadi N, Antoni S, Mwenda JM, Weldegebriel G, Biey JNM, Cheikh D, Fahmy K, Teleb N, Ashmony HA, Ahmed H, et al. Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008–16: findings from the Global Rotavirus Surveillance Network. Lancet Global Health. 2019;7(7):e893–e903. doi:10.1016/S2214-109X(19)30207-4.
   PubMed Web of Science ®Google Scholar
• Debellut F, Clark A, Pecenka C, Tate J, Baral R, Sanderson C, Parashar U, Atherly D. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study. Lancet Global Health. 2021;9(7):e942–e956. doi:10.1016/S2214-109X(21)00167-4.
   PubMed Web of Science ®Google Scholar
• Carvalho MF, Gill D. Rotavirus vaccine efficacy: current status and areas for improvement. Human Vaccin Immunother. 2018;15(6):1237–50. doi:10.1080/21645515.2018.1520583.
   PubMed Web of Science ®Google Scholar
• Stowe J, Andrews N, Ladhani S, Miller E. The risk of intussusception following monovalent rotavirus vaccination in England: a self-controlled case-series evaluation. Vaccine. 2016;34(32):3684–89. doi:10.1016/j.vaccine.2016.04.050.
   PubMed Web of Science ®Google Scholar
• Yih WK, Lieu TA, Kulldorff M, Martin D, McMahill-Walraven CN, Platt R, Selvam N, Selvan M, Lee GM, Nguyen M. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med. 2014;370(6):503–12. doi:10.1056/NEJMoa1303164.
   PubMed Web of Science ®Google Scholar
• Aliabadi N, Tate JE, Parashar UD. Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines. Clin Microbiol Infect. 2016;22:S128–S135. doi:10.1016/j.cmi.2016.03.007.
   PubMed Web of Science ®Google Scholar
• Apte A, Roy S, Bavdekar A, Juvekar S, Hirve S. Facilitators and barriers for use of rotavirus vaccine amongst various stakeholders and its implications for Indian context – a systematic review. Human Vaccin Immunother. 2018;18:1–8. doi:10.1080/21645515.2018.1489190.
   Google Scholar
• Groome MJ, Tate JE, Arnold M, Chitnis M, Cox S, de Vos C, Kirsten M, le Grange SM, Loveland J, Machaea S, et al. Evaluation of intussusception after oral monovalent rotavirus vaccination in South Africa. Clin Infect Dis. 2020;70(8):1606–12. doi:10.1093/cid/ciz431.
   PubMed Web of Science ®Google Scholar
• Clark A, Tate J, Parashar U, Jit M, Hasso-Agopsowicz M, Henschke N, Lopman B, Van Zandvoort K, Pecenka C, Fine P, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. Lancet Global Health. 2019;7(11):e1541–e1552. doi:10.1016/S2214-109X(19)30412-7.
   PubMed Web of Science ®Google Scholar
• Parker EP, Ramani S, Lopman BA, Church JA, Iturriza-Gómara M, Prendergast AJ, Grassly NC. Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol. 2018;13(1):97–118. doi:10.2217/fmb-2017-0128.
   PubMed Web of Science ®Google Scholar
• Lee B. Update on rotavirus vaccine underperformance in low- to middle-income countries and next-generation vaccines. Human Vaccin Immunother. 2021;17(6):1787–802. doi:10.1080/21645515.2020.1844525.
   PubMed Web of Science ®Google Scholar
• Steele AD, Victor JC, Carey ME, Tate JE, Atherly DE, Pecenka C, Diaz Z, Parashar UD, Kirkwood CD. Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries? Human Vaccin Immunother. 2019;15(6):1215–27. doi:10.1080/21645515.2018.1553593.
   PubMed Web of Science ®Google Scholar
• Fix A, Kirkwood CD, Steele D, Flores J. Next-Generation rotavirus vaccine developers meeting: summary of a meeting sponsored by PATH and the Bill & Melinda Gates Foundation (19–20 June 2019, Geneva). Vaccine. 2020;38(52):8247–54. doi:10.1016/j.vaccine.2020.11.034.
   PubMed Web of Science ®Google Scholar
• Kirkwood CD, Ma L-F, Carey ME, Steele AD. The rotavirus vaccine development pipeline. Vaccine. 2019;37(50):7328–35. doi:10.1016/j.vaccine.2017.03.076.
   PubMed Web of Science ®Google Scholar
• Groome MJ, Fairlie L, Morrison J, Fix A, Koen A, Masenya M, Jose L, Madhi SA, Page N, McNeal M, et al. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2020;20(7):851–63. doi:10.1016/S1473-3099(20)30001-3.
   PubMed Web of Science ®Google Scholar
• Bines JE, Thobari JA, Satria CD, Handley A, Watts E, Cowley D, Nirwati H, Ackland J, Standish J, Justice F, et al. Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. N Engl J Med. 2018;378(8):719–30; [accessed 2021 Sep 15]. 10.1056/NEJMoa1706804.
   PubMed Web of Science ®Google Scholar
• Anwari P, Debellut F, Pecenka C, Parwiz SM, Clark A, Groman D, Safi N. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan. Vaccine. 2018;36(51):7769–74. doi:10.1016/j.vaccine.2017.10.058.
   PubMed Web of Science ®Google Scholar
• Lusvan M-E, Debellut F, Clark A, Demberelsuren S, Otgonbayar D, Batjargal T, Purevsuren S, Groman D, Tate J, Pecenka C. Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia. Vaccine. 2019;37(6):798–807. doi:10.1016/j.vaccine.2018.12.056.
   PubMed Web of Science ®Google Scholar
• Lee H, Park SY, Clark A, Debellut F, Pecenka C, Kim DS, Kim HM, Kim JH, Cho H, Kim A-Y, et al. Cost-Effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: a South Korean study. Vaccine. 2019;37(35):4987–95. doi:10.1016/j.vaccine.2019.07.030.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy Y, Eliyas SK, Nair NP, Sakthivel M, Sarveswaran G, Chinnakali P. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. Vaccine. 2019;37(4):623–30. doi:10.1016/j.vaccine.2018.12.004.
   PubMed Web of Science ®Google Scholar
• Anwari P, Debellut F, Vodicka E, Clark A, Farewar F, Zhwak ZA, Nazary D, Pecenka C, Scott LaMontagne D, Safi N. Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan. Vaccine. 2020;38(6):1352–62. doi:10.1016/j.vaccine.2019.12.013.
   PubMed Web of Science ®Google Scholar
• Pempa LA, Luangasanatip N, Kingkaew P, Adhikari D, Isaranuwatchai W, Choiphel D, Pecenka C, Debellut F. Economic evaluation of rotavirus vaccination in children of Bhutan. Vaccine. 2020;38(32):5049–59. doi:10.1016/j.vaccine.2020.05.035.
   PubMed Web of Science ®Google Scholar
• Debellut F, Jaber S, Bouzya Y, Sabbah J, Barham M, Abu-Awwad F, Hjaija D, Ramlawi A, Pecenka C, Clark A, et al. Introduction of rotavirus vaccination in Palestine: an evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC. PloS One. 2020;15(2):e0228506. doi:10.1371/journal.pone.0228506.
   PubMed Web of Science ®Google Scholar
• 2019 growth domestic product per capita (current US$). The World Bank; [accessed 2021 Jan 15]. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
   Google Scholar
• Clark A, van Zandvoort K, Flasche S, Sanderson C, Bines J, Tate J, Parashar U, Jit M. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infect Dis. 2019;19(7):717–27. doi:10.1016/S1473-3099(19)30126-4.
   PubMed Web of Science ®Google Scholar
• Rogawski ET, Platts-Mills JA, Ross Colgate E, Haque R, Zaman K, Petri WA, et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. J Infect Dis Nat Immun Vaccine Effic. JID. 2018:861. doi:10.1093/infdis/jix668.
   Google Scholar
• WHO UNICEF coverage estimates WHO World Health Organization: immunization, vaccines and biologicals. Vaccine preventable diseases vaccines monitoring system 2020 Global Summary Reference Time Series: DTP3; [accessed 2021 Sep 15]. https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html .
   Google Scholar
• Clark A, Sanderson C. Timing of children’s vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet. 2009;373(9674):1543–49. doi:10.1016/S0140-6736(09)60317-2 .
   PubMed Web of Science ®Google Scholar
• Rotavirus vaccines WHO position paper. World Health Organization; 2013. p. 49–64. Weekly Epidemiological Record Report No.: 5. https://www.who.int/wer/2013/wer8805.pdf?ua=1 .
   Google Scholar
• Product information for vaccines and cold chain equipment. Gavi The Vaccine Alliance; [accessed 2020 Apr 16]. https://www.gavi.org/our-alliance/market-shaping/product-information-vaccines-cold-chain-equipment .
   Google Scholar
• Market Information for Access to Vaccines (MI4A). World Health Organization; [accessed 2020 Apr 16]. https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data#:~:text=MI4A%20Vaccine%20Purchase%20Database,database%20is%20updated%20every%20year .
   Google Scholar
• Auto-Disable AD syringes and Safety Boxes price data. UNICEF; [accessed 2020 Jul 14]. https://www.unicef.org/supply/reports/auto-disable-ad-and-re-use-prevention-rup-syringes-and-safety-boxes-price-data .
   Google Scholar
• Handling Fees. Supplies and Logistics. UNICEF; [accessed 2020 Jul 14]. https://www.unicef.org/supply/handling-fees .
   Google Scholar
• Immunization Costing Action Network. ImmunizationEconomics.Org; [accessed 2020 Apr 3]. https://immunizationeconomics.org/ican-home .
   Google Scholar
• Baral R, Nonvignon J, Debellut F, Agyemang SA, Clark A, Pecenka C. Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates. BMC Public Health. 2020;20(1):619. doi:10.1186/s12889-020-08595-8 .
   PubMed Web of Science ®Google Scholar
• Park J, Goldstein J, Haran M, Ferrari M. An ensemble approach to predicting the impact of vaccination on rotavirus disease in Niger. Vaccine. 2017;35(43):5835–41. doi:10.1016/2Fj.vaccine.2017.09.020 .
   PubMed Web of Science ®Google Scholar
• Rose J, Homa L, Meropol SB, et al. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: a model based analysis. PloS One. 2017:12e0187446. doi:10.1371/journal.pone.0187446 .
   Google Scholar
• Price J, Mooney J, Bain C, et al. National stakeholder preferences for next-generation rotavirus vaccines: results from a six-country study. Vaccine. 2022;40(2):370–79. doi:10.1016/j.vaccine.2021.11.009 .
   PubMed Web of Science ®Google Scholar